Published in
Esmo Open, Esmo Open, 4(1), p. e000079, 2016
DOI: 10.1136/esmoopen-2016-000079
Links
- ORCID
- Esmo Open
- [hdl.handle.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [iris.unito.it] | PDF
- [air.unimi.it] | PDF
- [europepmc.org] | PDF
Tools
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
Journal article published in 2016 by
Andrea Sartore-Bianchi,
Emanuele Valtorta,
Alessio Amatu 
,
Silvio Veronese,
Calogero Lauricella,
Erica Bonazzina,
Giulia Siravegna,
Mauro Truini,
Alberto Bardelli,
Salvatore Siena
,
Silvio Veronese,
Calogero Lauricella,
Erica Bonazzina,
Giulia Siravegna,
Mauro Truini,
Alberto Bardelli,
Salvatore Siena
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
We report the clinical and molecular characteristics of a 69-year-old woman with metastatic colorectal cancer, treated with the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody panitumumab, displaying peculiar molecular tumour heterogeneity at progression consisting of KRAS and MET amplification as distinct drivers associated with acquired resistance.